StockWatch
·
Biotechnology: Pharmaceutical Preparations
Corporate ActionJul 9, 2026, 04:42 PM

Inventiva Completes EIB Warrant Restructuring, Issues New Warrants

AI Summary

Inventiva announced the completion of its EIB warrant restructuring, a key component of its broader refinancing strategy. The company issued approximately 15.7 million new warrants to the European Investment Bank (EIB) and simultaneously cancelled all remaining Legacy EIB Tranche B Warrants. This move simplifies Inventiva's capital structure by eliminating anti-dilution protection mechanisms and a put option present in the old warrants, providing increased financial flexibility.

Key Highlights

  • Inventiva issued 15,677,573 new warrants (New EIB Warrants) to the European Investment Bank (EIB).
  • The New EIB Warrants represent approximately 6.5% of the company's current non-diluted share capital if fully exercised.
  • All remaining 2,444,654 Legacy EIB Tranche B Warrants were surrendered and cancelled.
  • The New EIB Warrants do not include specific contractual anti-dilution protection mechanisms or a put option.
  • New EIB Warrants expire on January 4, 2036, and are exercisable from August 30, 2026.
  • This completes the EIB warrant restructuring, a key step in Inventiva's broader refinancing efforts.